Macroaxis: Personalized Investing  
Macroaxis Country Selector USA  Change      Macroaxis User Registration Register    Macroaxis User Login Sign In
   
 US Market Open: Sep 2, 13:10 PM 2010 
  NYSE  6928.74  17.76  Index Moved Up   NASDAQ  2187.09  10.25  Index Moved Up 
 { and more.. }
Search is sponsered by  
  



Processing
Collecting necessary data for SLXP and NAII...

    
SLXP  Salix Pharmaceuticals Ltd.  vs  NAII  Natural Alternatives International Inc.
    

   ProfileMedia
39.54
  
Salix Quote
Intraday
 
Salix Intraday Quote
One Month
 0.44   Macroaxis: 1.13 Up   1.13%  
Salix Quote: BullSLXP Macroaxis: United States NASDAQ
Salix Pharmaceuticals Ltd.
 
Market Cap 2.286B   Book Value 6.472   EBITDA -12.0M   PEG Ratio 29.94   EPS -1.178   P/B Ratio 6.04   Short Ratio 6.50   Index Membership S&P   Sector Healthcare   Full Time Employees 395   Profile Get Profile for:   Drug Related Products   Open 39.06   High 39.75   Low 38.98   Volume 205.9 K   Target Price 50.60   Current EPS -1.178   This Year EPS 0.03   Next Year EPS 1.55   This Year PE 1303.33   Next Year PE 25.23  
    
    
    
Symbol  SLXP
Name  Salix Pharmaceuticals Ltd.
TypeStock
Country  Macroaxis: United States United States
Exchange  NASDAQ
 
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States.
    

Company Summary   more 

    
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor...
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or short-term therapy for adults; Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis; Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications that include the treatment of duodenal ulcer, benign gastric ulcer, and gastro esophageal reflux diseases; and Colazal capsules for the treatment of ulcerative colitis. In addition, Salix has products under development for the treatment of hepatic encephalopathy and irritable bowel syndrome, HIV-associated diarrhea, gastroenterology, and ulcerative proctitis or proctosigmoiditis. It has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; Biorex Laboratories Limited; Cedars?Sinai Medical Center; Clinical Development Capital Partnership; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Lupin, Ltd.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; and Wilmington Pharmaceuticals, LLC. The company was founded in 1989 and is headquartered in Morrisville, North Carolina.
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company?s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers? diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor...
    

Top Stories

 
 
 
 
 

Community Discussions

        
  
7.22
  
Natural Quote
Intraday
 
Natural Intraday Quote
One Month
 0.02   Macroaxis: 0.28 Up   0.28%  
Natural Quote: BullNAII Macroaxis: United States NGM
Natural Alternatives Internati
 
Market Cap 51.2M   Book Value 4.253   EBITDA 8.1M   EPS 0.71   P/E 10.14   P/B Ratio 1.69   Short Ratio 0.40   Sector Healthcare   Full Time Employees 181   Profile Get Profile for:   Drug Related Products   Open 7.15   High 7.26   Low 6.48   Volume 3.3 K   Current EPS 0.71   Current PE 10.14  
    
    
    
Symbol  NAII
Name  Natural Alternatives International Inc.
TypeStock
Country  Macroaxis: United States United States
Exchange  NGM
 
Natural Alternatives International, Inc. provides private label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers in the United States and internationally.
    

Company Summary   more 

    
Natural Alternatives International, Inc. provides private label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers in the United States and internationally. It offers strategic partnering services, including customized product formulation, clinical studies, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats, and labeling design. The company also develops, manufactures, and markets its own branded products under the Pathway to Healing product line through print ...
Natural Alternatives International, Inc. provides private label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers in the United States and internationally. It offers strategic partnering services, including customized product formulation, clinical studies, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats, and labeling design. The company also develops, manufactures, and markets its own branded products under the Pathway to Healing product line through print media and the Internet distribution channels. It manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. The company was founded in 1980 and is headquartered in San Marcos, California.
Natural Alternatives International, Inc. provides private label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers in the United States and internationally. It offers strategic partnering services, including customized product formulation, clinical studies, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats, and labeling design. The company also develops, manufactures, and markets its own branded products under the Pathway to Healing product line through print ...
    

Top Stories

 
 
 
 

Community Discussions